Register for our free featured webinar here: [ Ссылка ]
Read more on this story here: [ Ссылка ]
The US Food and Drug Administration (FDA) has approved Celgene and Acceleron’s Reblozyl (luspatercept-aamt) for the treatment of anemia in patients with beta thalassemia, on Friday. This is the first of its kind to treat patients with the rare blood disorder.
For more news stories, visit: [ Ссылка ]
Receive weekly news and webinar updates right in your inbox: [ Ссылка ]
Listen live and interact with featured speakers on our upcoming Life Science webinars: [ Ссылка ]
